insights_auto
Why is ABVX up 4,05%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
87,25 €
arrow_upward
+4,05%(+3,40) 1D
30 սեպ, 11:13:06 GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
85,95 €
High
87,35 €
Low
85,25 €
Mkt. cap
7,62 մլրդ
Avg. vol.
150,46 հզր
Volume
19,85 հզր
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,35 մլն
No. of employees
98
Open
85,95 €
High
87,35 €
Low
85,25 €
Mkt. cap
7,62 մլրդ
Avg. vol.
150,46 հզր
Volume
19,85 հզր
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,35 մլն
No. of employees
98
News stories
From web sources and news partners
Timothy Sykes
·
1 օր առաջ
ABVX Stock Draws Bullish Targets As Obefazimod Momentum Builds
Timothy Sykes
·
1 օր առաջ
ABVX Stock Gains Traction As Obefazimod Story Strengthens
MarketBeat
·
1 օր առաջ
Abivax (NASDAQ:ABVX) Shares Climb 4.4% - Should You Buy?
Ideal Investisseur
·
1 օր առաջ
Abivax share falls below €81.45, RSI in extreme oversold territory
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded04 դեկ, 2013 թ.
Headquarters-
Sector-
Websiteabivax.com